EUVIMEDEUVIMED entdecken
Crossref

DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia

Arnon Haran iD, Avital Wasserstrom, Vladimir Vainstein, Romi Kazoom, Ela Shai iD, Ariela Arad, Batia Roth iD, Noa Buchman, Yosef Kalish, Eran Zimran iD

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Arnon Haran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Mutation, Proto-Oncogene Proteins, Hemorrhage. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Thrombosis and bleeding events are major causes of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). The contribution of non‐driver mutations, in particular mutations in DNMT3A , TET2, and ASXL1 (collectively DTA) to thrombo‐hemorrhagic risk remains unclear.

Methods

We conducted a retrospective analysis of 180 patients with MPN undergoing next generation sequencing to evaluate the association between DTA mutations and major bleeding and thrombotic events occurring from 3 years prior to diagnosis through follow‐up. Patients were stratified by disease subtype, and Cox proportional hazards models were used for univariate and multivariate analyses.

Results

DTA mutations were present in 40% of the patients. 52 (29%) patients suffered from arterial or venous thrombotic events either following diagnosis or as early as 3 years prior to diagnosis, and 20 (11%) experienced major bleeding events during the same period. In patients with PV and ET, DNMT3A and TET2 (DT) mutations were significantly associated with venous thrombosis (HR 5.6, 95% CI 1.6–19.1) and were also associated with major bleeding in univariate analyses (HR 6.7, 95% CI 1.7–26.9). The association with venous thrombosis remained significant after multivariable adjustment, whereas the association with major bleeding was attenuated after adjustment for age and smoking status (HR 4.1, 95% CI 0.9–19.2). No such associations were observed in patients with myelofibrosis.

Conclusion

Our findings highlight an association between DT mutations and thrombotic and bleeding complications in patients with PV and ET and support further evaluation of molecular markers as contributors to thrombo‐hemorrhagic risk in MPN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-Binding ProteinsMutationProto-Oncogene ProteinsHemorrhageDNA (Cytosine-5-)-MethyltransferasesThrombocythemia, EssentialVenous ThrombosisPolycythemia VeraHumansDioxygenasesFemaleMaleDNA Methyltransferase 3AMiddle AgedAgedAdultRetrospective StudiesAged, 80 and over

Stichwörter der Autor:innen

DNMT3ATET2bleedingclonal hematopoiesismyeloproliferative disordersthrombosis

Substanzen

DioxygenasesTET2 protein, humanDNA-Binding ProteinsProto-Oncogene ProteinsDNA Methyltransferase 3ADNMT3A protein, humanDNA (Cytosine-5-)-Methyltransferases

Autor:innen und Institutionen

  • Department of Hematology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Faculty of Medicine, Hebrew University of Jerusalem, Israel.

ORCID-Profile: Arnon Haran, Ela Shai, Batia Roth, Eran Zimran

Zitieren

APA

Haran, A., Wasserstrom, A., Vainstein, V., Kazoom, R., Shai, E., Arad, A., Roth, B., Buchman, N., Kalish, Y., & Zimran, E. (2026). DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia. European Journal of Haematology. https://doi.org/10.1111/ejh.70271

Vancouver

Haran A, Wasserstrom A, Vainstein V, Kazoom R, Shai E, Arad A, et al. DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia. European Journal of Haematology. 2026. doi:10.1111/ejh.70271

BibTeX
@article{Haran2026,
  author = {Haran, Arnon and Wasserstrom, Avital and Vainstein, Vladimir and Kazoom, Romi and Shai, Ela and Arad, Ariela and Roth, Batia and Buchman, Noa and Kalish, Yosef and Zimran, Eran},
  title = {DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70271}
}
Kostenlos starten →